22/02/2026
Migraines are often explained as a simple vascular problem.
Blood vessels dilate. Pain follows.
But that model is incomplete.
What drives many migraines is neurovascular inflammatory signaling — a coordinated interaction between nerves, immune mediators, and mitochondrial stress.
At the center of this process is the trigeminal nerve.
When activated, it releases CGRP — calcitonin gene-related peptide — a neuropeptide that increases vascular permeability, promotes inflammation, and amplifies pain transmission.
But CGRP release doesn’t happen randomly.
It is often triggered by mitochondrial stress inside neurons.
When mitochondria lose efficiency — from sleep disruption, metabolic instability, oxidative stress, or hormonal fluctuation — ATP production declines and reactive oxygen species increase.
That redox imbalance sensitizes trigeminal neurons.
Once sensitized, even minor triggers can initiate:
• CGRP release
• Neurogenic inflammation
• Mast cell activation
• Cytokine amplification
• Central sensitization
This is why migraines often correlate with:
• Insulin resistance
• Sleep disruption
• Hormonal shifts
• Chronic stress
• Gut inflammation
The blood vessel dilation is real.
But it’s downstream.
The initiating signal is inflammatory and metabolic.
This also explains why modern therapies now target CGRP signaling directly — because blocking vascular dilation alone does not address the upstream neural-immune cascade.
Resolution matters here.
When inflammatory tone stabilizes:
• Trigeminal sensitivity decreases
• CGRP release normalizes
• Mitochondrial efficiency improves
• Neural excitability lowers
What supports that shift?
• Stabilizing blood glucose
• Sleep optimization
• Magnesium to support neuronal excitability balance
• Omega-3 intake to support pro-resolving mediator production
• Riboflavin (B2) for mitochondrial support
• Stress regulation to reduce sympathetic overdrive
Migraines are not just a vessel problem.
They are a signaling problem.
And signaling can be recalibrated.
